Literature DB >> 3883902

Topical minoxidil therapy in hereditary androgenetic alopecia.

R L De Villez.   

Abstract

A randomized double-blind trial of topical minoxidil therapy was carried out on 56 patients with hereditary male pattern baldness. The subjects selected were required to have a discernible balding patch, a minimum of 2.5 cm in diameter on the vertex of the head where the hairs could be counted and photographed. Minoxidil, 1.0 mL, was applied twice a day to the scalp beginning at the balding vertex and spreading centrifugally around the scalp. Cosmetically acceptable hair growth was achieved in 18 patients (32%). The most notable indicators for regrowth of hair were the number of indeterminate hairs initially present, the duration of baldness, and the size of the balding area. No serious systemic or cutaneous side effects were noted.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3883902     DOI: 10.1001/archderm.121.2.197

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  10 in total

1.  Immunohistochemical and autoradiographic findings suggest that minoxidil is not localized in specific cells of vibrissa, pelage, or scalp follicles.

Authors:  B V Zelei; C J Walker; G A Sawada; T T Kawabe; K A Knight; A E Buhl; G A Johnson; A R Diani
Journal:  Cell Tissue Res       Date:  1990-12       Impact factor: 5.249

2.  Dermatology: minoxidil.

Authors:  V H Price
Journal:  West J Med       Date:  1985-08

Review 3.  Topical minoxidil. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in alopecia areata and alopecia androgenetica.

Authors:  S P Clissold; R C Heel
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

4.  Topical minoxidil: cardiac effects in bald man.

Authors:  F H Leenen; D L Smith; W P Unger
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

Review 5.  Treatments for androgenetic alopecia and alopecia areata: current options and future prospects.

Authors:  V M Meidan; E Touitou
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Short-Term Efficacy of Autologous Cellular Micrografts in Male and Female Androgenetic Alopecia: A Retrospective Cohort Study.

Authors:  Shadi Zari
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-11-19

Review 7.  Alopecia and hirsuties. Current concepts in pathogenesis and management.

Authors:  J H Barth
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

8.  Keratinocyte growth factor is an important endogenous mediator of hair follicle growth, development, and differentiation. Normalization of the nu/nu follicular differentiation defect and amelioration of chemotherapy-induced alopecia.

Authors:  D M Danilenko; B D Ring; D Yanagihara; W Benson; B Wiemann; C O Starnes; G F Pierce
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

Review 9.  Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.

Authors:  Mark S Nestor; Glynis Ablon; Anita Gade; Haowei Han; Daniel L Fischer
Journal:  J Cosmet Dermatol       Date:  2021-11-06       Impact factor: 2.189

10.  A Comparative Study of Microneedling with Platelet-rich Plasma Plus Topical Minoxidil (5%) and Topical Minoxidil (5%) Alone in Androgenetic Alopecia.

Authors:  Kaksha B Shah; Aarti N Shah; Rekha B Solanki; Ranjan C Raval
Journal:  Int J Trichology       Date:  2017 Jan-Mar
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.